Skip to main content

Association of CD58 polymorphism and multiple sclerosis in Malaysia: a pilot study

Abstract

Background

Multiple sclerosis is an immune mediated disease targeting the central nervous system. Association of non-human leukocyte antigen gene, CD58, with multiple sclerosis has been reported in several populations but is unclear among Southeast Asians. This pilot study was conducted to explore the association between CD58 polymorphism and multiple sclerosis among the Malay population in Malaysia.

Methods

Blood samples were collected from 27 multiple sclerosis patients, and compared with 58 age- and gender matched healthy individuals. All patients were tested negative for anti-aquaporin 4. DNA was extracted from the blood and genotyped for 3 single nucleotide polymorphisms rs12044852, rs2300747 and rs1335532 of gene CD58 by real-time PCR.

Results

The majority of multiple sclerosis patients were female (85.2%). The general mean age of onset was 30.5 years. Genotyping results showed that frequencies of the alleles were between 40 and 50% for MS patients and healthy individuals. Association (allelic model) between multiple sclerosis and CD58 gene polymorphism alleles rs12044852 (p = 0.410), rs2300747 (p = 0.881) and rs1335532 (p = 0.407) were indistinct.

Conclusions

The impact of the CD58 gene polymorphism was not prominent in this pilot study, implying that genetic composition contributing to multiple sclerosis may be different between different populations, thus results in a heterogeneity of disease manifestation and distribution.

Background

Multiple Sclerosis (MS) is an immune-mediated disease characterized by inflammation and demyelination of the central nervous system (CNS). MS patients can present with a broad spectrum of neurological symptoms such as visual loss, muscle weakness, sensory loss, incoordination, cognitive dysfunction and bladder problems [1]. A systemic analysis of MS has reported that age-standardized prevalence was greater than 120 cases per 100,000 population in North America and some northern European countries, moderate (60–120 per 100,000) in some countries in Europe and Australasia, and lower in Africa, Asia and northern South America region (5 per 100 000) [2, 3]. In Malaysia, the prevalence of MS was estimated to range from 2 to 3 per 100,000 [4, 5].

The development of MS is commonly associated with the interaction between genetic susceptibility and environmental factors. Genetic association of MS, especially the variation in human leukocyte antigen (HLA) location on chromosome 6, has been generally considered as the highest risk for the disease development [6]. However, the influence of the HLA gene alone is insufficient to fully explain the role of genetic in the pathogenesis of the disease. A genome wide association study of MS patients among the United States (US) and United Kingdom (UK) was performed by the International Multiple Sclerosis Genetics Consortium (IMSGC) in 2007. They found that several single nucleotide polymorphisms (SNPs) from the non-HLA region were highly associated with MS [7]. One of the MS related non-HLA genes is CD58.

The CD58 gene is located on chromosome one and it encodes a member of the T lymphocytes CD2 protein ligand, which plays an important role in signal transduction in T cell activation [8, 9]. Regulation of T cells is crucial in maintaining the body’s immune response and tolerance towards self and foreign antigens. Failure of immune tolerance towards self-antigens results in autoimmunity. The CD58 SNPs have been studied in European ancestry [10, 11] but little is known about their association with MS in Asian, especially in Southeast Asian. Therefore, in this study, we aimed to explore and investigate the association of several CD58 SNPs and MS in the Malay population in Malaysia.

Methods

Subjects of study

Samples for this study consisted of 27 MS patients, who were recruited from the Neurology Clinic, of Hospital Kuala Lumpur. This study enrolled patients of Malay ancestry and were diagnosed with Multiple Sclerosis (MS) by a neurologist based on the revised McDonald criteria of 2017 [12]. Clinical subtypes of the disease included relapsing–remitting MS (RRMS) and secondary progressive MS (SPMS). Demographic data and characteristic of patients such as duration of disease, age onset, MRI results (infratentorial lesion and juxtacortical lesion) and Expanded Disability Status Scale (EDSS) scores were collected. All samples were tested for anti-aquaporin 4 antibodies using commercially available kit (Euroimmun, Lubeck, Germany). Patients with positive anti-aquaporin 4 antibodies were excluded from the study. The control group comprised 58 biological unrelated individuals of the same ethnic background and similar age. Informed consent was obtained from all patients and control individuals participating in this study and their anonymity was preserved. This study was approved by the Medical Research and Ethics Committee of Malaysia Ministry of Health (NMRR-13-1029-18067).

Sample preparation and genotyping

DNA was extracted from blood samples according to the standard method using the commercial DNA extraction kit (Qiagen, Germany). Three SNPs (rs12044852, rs1335532 and rs2300747) in CD58 gene were selected based on findings of genome wide association studies (GWAS) and were reported to be highly associated with MS [7, 11, 13]. The 3 SNPs were genotyped for all study subjects and control using Taqman assay (Applied Biosystems, USA): Taqman SNP Genotyping assay C_31433800_10 (rs12044852), C_15755405_10 (rs2300747) and C_8700717_10 (rs1335532), on the ABI 7500 Fast Real-time PCR system (Thermo Fisher Scientific, USA).

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics version 22 for Windows (IBM Corp, USA). Allele frequencies for MS patients and healthy controls were calculated and compared to healthy controls. The association between CD58 polymorphism and MS patients’ characteristics was analysed using Chi square or two-tailed Fisher’s exact test, odd ratios (OR) and 95% confidence interval (95% CI) were calculated. Value of p ≤ 0.05 was considered statistically significant.

Results

Our study population consisted of 27 Malay MS patients, predominantly female, with female to male ratio of 5.8:1. Control groups comprised 52 females and 6 males of healthy individuals. The demographic and clinical features of the study population are shown in Table 1. Majority of MS patients in this study population were diagnosed as RRMS (81.5%).

Table 1 Demographic and clinical features of study subjects

Allelic prevalence for each of the CD58 SNPs studied shows a range of 40 to 50% for each allele in both MS patients and controls (Table 2). Frequencies of CD58 haplotypes for this study population are shown in Table 3. Table 4 shows the association analysis of the CD58 SNP alleles rs12044852 (p = 0.410), rs1335532 (p = 0.881) and rs2300747 (p = 0.407) between MS patients and controls. Analysis of the results revealed no significant association between CD58 SNPs and age of onset, MRI parameters and disease activity. CD58 SNPs were also not significantly different between types of MS.

Table 2 Genotype distribution and allele frequency CD58 SNPs in MS patients and controls
Table 3 Frequency of CD58 haplotypes in this study
Table 4 Allelic analysis of CD58 SNPs in MS patients and control

Discussion

Single nucleotide polymorphisms (SNPs) are the most common type of DNA polymorphisms in human and their relations with autoimmune diseases such as MS are noteworthy. Association of SNPs in non-HLA genes and autoimmune diseases has been reported in various studies involving the US and European population in the last decades [14, 15].

For MS, one of the candidate non-HLA genes reported to be associated with the disease is CD58 [16]. It is suggested that alteration of CD58 expression affects the regulation of FoxP3, a protein highly expressed in regulatory T cells (Treg), leading to functional changes in Treg cells and influence the body’s immune response against its own cells. Dysfunction or reduction of Treg has been reported in various studies of autoimmune diseases including MS [17]. The expression of CD58 mRNA has been shown to be increased significantly in samples collected from MS patients during remission than those sampled during relapse [13].

The demographic characteristic of this study is in agreement with findings of other studies. Age of onset in this study population ranged from 16 to 56 years old, with mean of 30.5 ± 10.3 years which falls within the range of findings in other studies around the region: 28.6 ± 9.9 years in another study in Malaysia [18] and 32.7 ± 11.5 years in Thailand [19]. In South India, the age of onset was noted at 38.3 ± 12.8 years [20]. Out of 27 MS patients in this study, about 85.2% were females and 14.8% were males, with female to male ratio of 5.8:1. The ratio is consistent with an analysis of data from the Danish Multiple Sclerosis Registry that showed the incidence in women doubled between 1950 and 2009, while the increases among men were relatively moderate [21]. The rapid change in incidence among women might be due to environmental changes such as the rise in obesity, increased cigarette smoking, and changes in the frequency of breastfeeding infants [21, 22].

In this pilot study, we investigated the possible association of CD58 SNPs, namely rs2300747, rs12044852 and rs1335532, with MS amongst Malay population in Malaysia. Our results showed that the frequency of rs2300747G was higher in the control group compared to the MS patients, suggesting a potential of a protective value in rs2300747G, although the difference was statistically insignificant. A study done by De Jager et al. indicated that rs2300747G was a protective allele associated with MS and that East Asian cell lines expressed higher frequencies of rs2300747G compared to the cell lines of Europe ancestry, which might explain a lower frequency of MS amongst Asians [11]. This is also supported by a meta-analysis done by Liu et al. [23] which reported polymorphism of rs2300747G as a protective allele against MS. However, findings of SNP rs2300747 and MS were inconsistent in different populations. Like our results, no evidence of protective allele in SNP rs2300747 was found in a study on the association of non-MHC region and MS among Indian population in India [24].

In a replication GWAS study conducted by The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) which analysed more than 1500 MS cases, it was reported that SNP rs1335532 of CD58 is one of the non-HLA SNPs that was highly associated with MS [13]. However, the same SNP has been reported to be significantly associated with neuromyelitis optica spectrum disorders (NMOSD), another spectrum of inflammatory demyelinating disease, in a case–control study of Koreans [25, 26]. On the other hand, the other CD58 SNPs, rs12044852, has been repeatedly reported to be associated with MS [27, 28]. A case–control study involving 200 MS patients and 200 healthy controls in a subset of Iranian population reported that the rs12044852 polymorphism of CD58 has a profound effect on the onset of MS but not significantly associated with patients’ gender, disease severity and type of MS [29]. Our results showed that the rs12044852 polymorphism was not significantly associated with MS. This is also similar to a study focused on genetic susceptibility to MS in African Americans, that showed rs12044852 and rs2300747 were not significantly associated with MS [30].

There were a number of limitations in our study which possibly restricted the analysis of the results and affected the outcome of the study. Compared with other studies on SNPs [13, 31], the number of patients and controls recruited in this study was relatively small for genetic association study and may not represent the true population. Small sample size also has less statistical power and could introduce bias to this study, leading to insignificant results. Although a larger sample size could increase statistical power, it could also be costly and takes longer time frame to complete the sample collection due to the relatively low frequency of autoimmune diseases around the region. Another option that can be considered to improve this study is by increasing the sample size of the control to 1:4 case–control ratio if the assumptions of model can be fulfilled [32]. Another limitation in this study that can be improved is the location of sample collection. Due to location of the hospital, patients recruited in this study were mainly from the central urban region of Peninsular Malaysia. This could introduce bias as the Malay population in Malaysia can be clustered into a few sub-ethnic groups that could be genetically different [33]. In addition to that, like other autoimmune diseases, the development of MS involves a complex interaction between genetic susceptibility and environmental factors. CD58 gene may play an indirect role in disease development and the differences in other genetic components of our study population may have contributed to the outcome.

In conclusion, our exploratory study did not show significant association between CD58 SNPs (rs12044852, rs1335532 and rs2300747) and MS in our study population. However, further investigations with optimal sample size, more genetic markers and correlation with environmental factors are necessary to help shed some light on this disease in our country.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

MS:

Multiple sclerosis

HLA:

human leukocyte antigen

SNPs:

single nucleotide polymorphisms

RRMS:

relapsing–remitting MS

SPMS:

secondary progressive MS

EDSS:

Expanded Disability Status Scale

References

  1. 1.

    Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409–16.

    CAS  Article  Google Scholar 

  2. 2.

    Chong HT. Multiple sclerosis in South East Asia and diagnostic criteria for Asians. Neurol Asia. 2008;13:145–6.

    Google Scholar 

  3. 3.

    GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–80.

    Article  Google Scholar 

  4. 4.

    Chong HT, Tan CT. A review of multiple sclerosis with Asian perspective. Med J Malaysia. 2008;63:356–61.

    CAS  PubMed  Google Scholar 

  5. 5.

    Tan C-T. Multiple sclerosis in Malaysia. Arch Neurol. 1988;45:624–7.

    CAS  Article  Google Scholar 

  6. 6.

    International multiple sclerosis genetics consortium. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77:454–67.

    Article  Google Scholar 

  7. 7.

    International multiple sclerosis genetics consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–62.

    Article  Google Scholar 

  8. 8.

    Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today. 1996;17:177–87.

    CAS  Article  Google Scholar 

  9. 9.

    Mestas J, Hughes CCW. Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation. J Immunol. 2001;167:4378–85.

    CAS  Article  Google Scholar 

  10. 10.

    Hoppenbrouwers IA, Aulchenko YS, Janssens AC, Ramagopalan SV, Broer L, Kayser M, et al. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J Hum Genet. 2009;54:676–80.

    CAS  Article  Google Scholar 

  11. 11.

    De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, et al. The role of the CD58 locus in multiple sclerosis. PNAS. 2009;106:5264–9.

    Article  Google Scholar 

  12. 12.

    Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.

    Article  Google Scholar 

  13. 13.

    Bahlo M, Booth DR, Broadley SA, Brown MA, Foote SJ, Griffiths LR, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8.

    CAS  Article  Google Scholar 

  14. 14.

    Sharma A, Liu X, Hadley D, Hagopian W, Liu E, Chen W-M, et al. Identification of non-HLA genes associated with celiac disease and country-specific differences in a large, international pediatric cohort. PLoS ONE. 2016;11:e0152476.

    Article  Google Scholar 

  15. 15.

    Steck AK, Bugawan TL, Valdes AM, Emery LM, Blair A, Norris JM, et al. Association of Non-HLA genes with Type 1 diabetes autoimmunity. Diabetes. 2005;54:2482–6.

    CAS  Article  Google Scholar 

  16. 16.

    Bahreini SA, Jabalameli MR, Saadatnia M, Zahednasab H. The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol. 2010;229:5–15.

    CAS  Article  Google Scholar 

  17. 17.

    Viglietta V. Loss of functional suppression by CD4 + CD25 + regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971–9.

    CAS  Article  Google Scholar 

  18. 18.

    Viswanathan S, Rose N, Masita A, Dhaliwal JS, Puvanarajah SD, Rafia MH, et al. Multiple sclerosis in Malaysia: demographics, clinical features, and neuroimaging characteristics. Mult Scler Int. 2013. https://doi.org/10.1155/2013/614716.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Siritho S, Prayoonwiwat N, Pulkes T, Chankrachang S, Laptikultham S, Nidhinandana S, et al. A retrospective study of multiple sclerosis in Thailand. Neurol Asia. 2010;15(3):253–61.

    Google Scholar 

  20. 20.

    Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler. 2014;20:1651–3.

    Article  Google Scholar 

  21. 21.

    Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurol. 2018;90:e1954–63.

    Article  Google Scholar 

  22. 22.

    Langer-Gould A, Smith JB, Hellwig K, Gonzales E, Haraszti S, Koebnick C, et al. Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurol. 2017;89:563–9.

    Article  Google Scholar 

  23. 23.

    Liu J, Liu X, Liu Y, Deng S, Huang H, Chen Q, et al. Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: a meta-analysis. Meta Gene. 2016;9:97–103.

    Article  Google Scholar 

  24. 24.

    Pandit L, Ban M, Sawcer S, Singhal B, Nair S, Radhakrishnan K, et al. Evaluation of the established non-MHC multiple sclerosis loci in an Indian population. Mult Scler J. 2011;17:139–43.

    CAS  Article  Google Scholar 

  25. 25.

    Kim JY, Bae JS, Kim HJ, Shin HD. CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. BMC Neurol. 2014;14:57.

    Article  Google Scholar 

  26. 26.

    Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurol. 2015;85:177–89.

    Article  Google Scholar 

  27. 27.

    Hecker M, Blaschke J, Blaschke P, Fitzner B, Koczan D, Thiesen H-J, et al. CD58 and multiple sclerosis: genetic association, gene expression and prognostic value (P6.156). Neurology. 2014;82:P6.156.

    Google Scholar 

  28. 28.

    Brynedal B, Lima Bomfim I, Olsson T, Duvefelt K, Hillert J. Differential expression, and genetic association, of CD58 in Swedish multiple sclerosis patients. PNAS. 2009;106:23.

    Article  Google Scholar 

  29. 29.

    Torbati S, Karami F, Ghaffarpour M, Zamani M. Association of CD58 polymorphism with multiple sclerosis and response to interferon ß therapy in a subset of Iranian population. Cell J. 2015;16(4):506–13.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010;11:343–50.

    CAS  Article  Google Scholar 

  31. 31.

    Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009;18:767–78.

    CAS  Article  Google Scholar 

  32. 32.

    Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform. 2012;10:117.

    Article  Google Scholar 

  33. 33.

    Hatin WI, Nur-Shafawati AR, Zahri M-K, Xu S, Jin L, Tan S-G, et al. Population genetic structure of Peninsular Malaysia malay sub-ethnic groups. PLoS ONE. 2011;6:e18312.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Director General of Health Malaysia for his permission to publish this article.

Funding

This study was funded by National Institute of Health Malaysia (NMRR-13-1029-18067).

Author information

Affiliations

Authors

Contributions

CYM, SV, SM, AYY and MA designed and conceptualized the study; CYM, SV, NMN, SS, BK and SM acquired and analyzed data; all authors were involved in interpretation of data; all authors were involved in drafting, revising the manuscript and approving the manuscript; CYM was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Masita Arip.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from all participants. Identification details were removed to maintain the anonymity. This study was approved by Medical Research and Ethics Committee of Malaysia Ministry of Health (NMRR-13-1029-18067).

Consent for publication

Not applicable.

Competing interest

The authors declare that they have no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ching, Y., Viswanathan, S., Mohamed Nor, N. et al. Association of CD58 polymorphism and multiple sclerosis in Malaysia: a pilot study. Autoimmun Highlights 10, 13 (2019). https://doi.org/10.1186/s13317-019-0123-7

Download citation

Keywords

  • Multiple sclerosis
  • CD58 polymorphism
  • Single nucleotide polymorphism